|
CN112168960A
|
|
Use of anti-VEGF antibody and anti-ANG2 antibody for the preparation of a medicament for the treatment of tumors with Ras mutations
|
|
CN112168971A
|
|
Application of anti-VEGF antibody and PDGF/PDGFR inhibitor in preparation of medicines for treating FGF 2-expressing tumors
|
|
CN112007025A
|
|
Application of mirabegron in preparation of medicine for preventing and/or treating malignant tumor
|
|
CN112010971A
|
|
Application of anti-VEGF antibody in preparation of medicine for preventing and/or treating fatty liver
|
|
CN110415780A
|
|
A kind of administration control method, drug delivery device and terminal device
|
|
CN110415781A
|
|
A kind of drug delivery device
|
|
CN110402853A
|
|
The detection model and its construction method of immunocyte killing tumour ability and application
|
|
CN110227159A
|
|
The drug and CPT1a inhibitor for improving entity tumor confrontation blood vessel drug eluting drug resistance are in application wherein
|
|
CN110232962A
|
|
A kind of leg training system
|
|
CN110227249A
|
|
A kind of upper limb training system
|
|
CN109966495A
|
|
A kind of prevention and/or the application in the drug of drug and VEGFR1 inhibitor for the treatment of fat metabolism disease
|
|
CN109966494A
|
|
A kind of prevention and/or the application in the drug of drug and VEGFR1 inhibitor for the treatment of diabetes
|
|
CN109893656A
|
|
MiR-327 inhibitor and/or FGF10 promotor are preventing and/or are treating the application in fat metabolism disease drug
|
|
CN109893655A
|
|
The application of miR-327 inhibitor and/or FGF10 promotor in the drug for preventing and/or treating diabetes
|
